Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Zoetis stock price increased by 8.6% since last publication, underperforming S&P 500 index. Company raised full-year guidance, expecting double-digit growth, driven by DTC strategy and new products. Upgraded rating to 'Buy' with $210 target price per share, expecting revenue growth and margin expansion.
Zoetis Inc Is Being Investigated By The Schall Law Firm And Investors With Losses Are Encouraged To Make Contact
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis Raises Guidance on Revenue Growth
Zoetis (ZTS) stock surged in intraday trading Tuesday after the company beat second-quarter revenue expectations and raised its full-year guidance.
Animal Health Firm Zoetis Clocks Strong Q2 Earnings, Companion Animal Operations Boost Confidence For 2024
On Tuesday, Zoetis Inc ZTS stock is trading higher after the company reported better-than-expected second-quarter financial results and raised its 2024 guidance above estimates.
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
Why Zoetis Stock Was Moving Higher Tuesday
Zoetis beat estimates on the top and bottom lines. Both the companion animal and livestock segments delivered solid growth.
Zoetis Lifts Revenue, Profit Outlook
Adjusted earnings per share topped analyst estimates. Net income fell 7% year over year to $624 million.
Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.41 per share a year ago.
Zoetis lifts 2024 results forecasts on strong demand for pet treatments
Animal healthcare company Zoetis raised its annual profit and revenue forecasts on Tuesday, betting on strong demand for its medicines and vaccines for pets.
Zoetis (ZTS) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Zoetis (ZTS) closed at $182.42, indicating a +1.32% shift from the previous trading day.
Unveiling Zoetis (ZTS) Q2 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
